Next Article in Journal / Special Issue
A New Ethical Challenge for Institutional Review Boards (IRBs)/Ethics Committees (ECs) in the Assessment of Pediatric Clinical Trials
Previous Article in Journal
Understanding the Health Behaviors of Survivors of Childhood and Young-Adult Cancer: Preliminary Analysis and Model Development
Previous Article in Special Issue
Cystic Fibrosis Treatment: A Paradigm for New Pediatric Medicines, Globalization of Drug Development and the Role of the European Medicines Agency
Open AccessReview

Safety of Excipients in Pediatric Formulations—A Call for Toxicity Studies in Juvenile Animals?

F. Hoffmann-La Roche Ltd., Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel CH-4070, Switzerland
Academic Editors: Johannes N. van den Anker and Klaus Rose
Children 2015, 2(2), 191-197; https://doi.org/10.3390/children2020191
Received: 3 March 2015 / Revised: 2 April 2015 / Accepted: 27 April 2015 / Published: 15 May 2015
(This article belongs to the Collection Development of Medicines for Paediatric and Rare Diseases)
The development of drug products for pediatric use often requires age-appropriate formulations which can be more complex and may involve a broader range of excipients than adult dosage forms. Excipients established for adult use are not always appropriate for use in children because they can affect children differently than adults. Therefore, a comprehensive safety assessment of the excipients in a pediatric formulation is essential before use, referring to existing safety data from adult human and animals as well as safety data from pediatric use and juvenile toxicity studies, when available. The overall risk assessment needs to consider the safety risk from the excipients and the extent to which the risk from the disease as such will be ameliorated by the drug formulation. Non-clinical safety studies in juvenile animals are used to assess for specific toxicities or sensitivities of excipients and for establishing safe exposures in pediatric age groups. As for any active ingredient, non-clinical safety studies in juvenile animals should only be performed for excipients if important for clinical risk assessment and labelling. Pharmaceutical companies should be critical of excessive demands for juvenile animal testing, particularly of excipients when critically needed for significant therapeutic benefit. View Full-Text
Keywords: pediatric drug development; pediatric formulations; safety; juvenile animal studies pediatric drug development; pediatric formulations; safety; juvenile animal studies
MDPI and ACS Style

Schmitt, G. Safety of Excipients in Pediatric Formulations—A Call for Toxicity Studies in Juvenile Animals? Children 2015, 2, 191-197.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop